Literature DB >> 30420718

Intratumoral IFN-α gene delivery reduces tumor-infiltrating regulatory T cells through the downregulation of tumor CCL17 expression.

Aya Hirata1,2, Hisayoshi Hashimoto1, Chihiro Shibasaki1, Kenta Narumi1, Kazunori Aoki3.   

Abstract

The effect of IFN-α on the immunosuppressive tumor microenvironment is not fully understood. We previously reported that intratumoral IFN-α gene transduction decreased the frequency of regulatory T cells (Tregs) in the tumor by inducing the secretion of IL-6 from dendritic cells. In this study, we examined whether IFN-α affects the trafficking of Tregs to the tumor. Since CT26 cells expressed CCL17 among Treg-attracting chemokines, we focused on its role in IFN-α-mediated Treg suppression. IFN-α directly suppressed CCL17 production from CT26 cells in vitro, and IFN-α transduction reduced CCL17 expression in tumors in vivo. Next, to investigate whether CCL17 downregulation is related to the suppression of Treg trafficking, CCL17-downregulated CT26 cells produced using short hairpin RNA (CT26-shCCL17) were inoculated into mice. The frequency of Tregs in CT26-shCCL17 tumors was reduced and tumor growth was suppressed. Finally, to examine the combinatorial effect of IFN-α expression with CCL17 downregulation, IFN-α was transduced into CT26-shCCL17 tumors. This resulted in an elevation of CT26-specific CD8+ T cells and the complete eradication of tumors. This study shows a novel mechanism of IFN-α-mediated Treg suppression, and combining IFN-α gene therapy with strong CCL17 downregulation could offer a promising strategy for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30420718     DOI: 10.1038/s41417-018-0059-5

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  2 in total

1.  IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells.

Authors:  S Gupta; M Jiang; A B Pernis
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

Review 2.  Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.

Authors:  L M Pfeffer; C A Dinarello; R B Herberman; B R Williams; E C Borden; R Bordens; M R Walter; T L Nagabhushan; P P Trotta; S Pestka
Journal:  Cancer Res       Date:  1998-06-15       Impact factor: 12.701

  2 in total
  11 in total

1.  Identification of a Six-Gene Signature for Predicting the Overall Survival of Cervical Cancer Patients.

Authors:  Xiao Huo; Xiaoshuang Zhou; Peng Peng; Mei Yu; Ying Zhang; Jiaxin Yang; Dongyan Cao; Hengzi Sun; Keng Shen
Journal:  Onco Targets Ther       Date:  2021-02-05       Impact factor: 4.147

Review 2.  Opposing Roles of Type I Interferons in Cancer Immunity.

Authors:  Giselle M Boukhaled; Shane Harding; David G Brooks
Journal:  Annu Rev Pathol       Date:  2020-12-02       Impact factor: 23.472

Review 3.  Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.

Authors:  Chunxiao Li; Ping Jiang; Shuhua Wei; Xiaofei Xu; Junjie Wang
Journal:  Mol Cancer       Date:  2020-07-17       Impact factor: 27.401

4.  Screening and Identification of Prognostic Tumor-Infiltrating Immune Cells and Genes of Endometrioid Endometrial Adenocarcinoma: Based on The Cancer Genome Atlas Database and Bioinformatics.

Authors:  Bingnan Chen; Di Wang; Jiapo Li; Yue Hou; Chong Qiao
Journal:  Front Oncol       Date:  2020-12-01       Impact factor: 6.244

Review 5.  DNA Damage Repair in Brain Tumor Immunotherapy.

Authors:  Shihong Zhao; Boya Xu; Wenbin Ma; Hao Chen; Chuanlu Jiang; Jinquan Cai; Xiangqi Meng
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

6.  Development and Validation of a Pyroptosis-Related Signature for Predicting Prognosis in Hepatocellular Carcinoma.

Authors:  Jianfeng Ding; Xiaobo He; Wei Luo; Weiguo Zhou; Rui Chen; Guodong Cao; Bo Chen; Maoming Xiong
Journal:  Front Genet       Date:  2022-01-24       Impact factor: 4.599

7.  Local Release of TGF-β Inhibitor Modulates Tumor-Associated Neutrophils and Enhances Pancreatic Cancer Response to Combined Irreversible Electroporation and Immunotherapy.

Authors:  Huiming Peng; Jian Shen; Xin Long; Xiaoqi Zhou; Jiaqi Zhang; Xina Xu; Teng Huang; Hui Xu; Shuguo Sun; Chun Li; Ping Lei; Heshui Wu; Jun Zhao
Journal:  Adv Sci (Weinh)       Date:  2022-02-07       Impact factor: 16.806

Review 8.  Type I interferon-mediated tumor immunity and its role in immunotherapy.

Authors:  Renren Yu; Bo Zhu; Degao Chen
Journal:  Cell Mol Life Sci       Date:  2022-03-16       Impact factor: 9.207

Review 9.  Nucleic Acid-Based Approaches for Tumor Therapy.

Authors:  Simone Hager; Frederic Julien Fittler; Ernst Wagner; Matthias Bros
Journal:  Cells       Date:  2020-09-09       Impact factor: 6.600

Review 10.  Type I and II Interferons in the Anti-Tumor Immune Response.

Authors:  Sarah E Fenton; Diana Saleiro; Leonidas C Platanias
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.